Table 2. Patient and tumor characteristics.
| Characteristics | PPGLs | Non-PPGL tumors | Statistical value |
|---|---|---|---|
| Age (years) | t=−0.630, P=0.532 | ||
| Median | 40.5 | 52 | |
| Range | 16–74 | 15–83 | |
| Gender, n (%) | χ2=0.011, P=0.917 | ||
| Male | 23 (60.5) | 13 (61.9) | |
| Female | 15 (39.5) | 8 (38.1) | |
| Site of analyzed lesion, n (%) | χ2=0.438, P=0.508 | ||
| PCC | 22 (57.9) | – | |
| Retroperitoneal PGL | 15 (42.1) | – | |
| Mediastinal PGL | 1 | – | |
| Adrenal gland | – | 14 (66.7) | |
| Retroperitoneal | – | 7 (33.3) | |
| Tumor size analyzed (mm) | t=−0.230, P=0.819 | ||
| Median | 45 | 47 | |
| Range | 19–189 | 21–189 | |
| Biochemical tests | Z=−6.558, P=0.001 | ||
| Positive | 30 | 0 | |
| Borderline | 6 | 1 | |
| Negative | 2 | 20 | |
| Mutation | |||
| SDHD | 1 | – | |
| VHL | 2 | – | |
| RET | 4 | – | |
| Unknown | 32 | – | |
| Pathology | |||
| PNST | – | 6 | |
| AA | – | 4 | |
| Ganglioneuroma | – | 2 | |
| Hemolymphangioma | – | 2 | |
| Adenoid tumor of adrenal gland | – | 1 | |
| GIST | – | 1 | |
| Angiomyolipoma | – | 1 | |
| RSF | – | 1 | |
| AC | – | 2 | |
| Metastasis of RCC | – | 1 | |
| SUVmax of the tumor | 22.6±16.1 | 4.6±3.3 | Z=−5.098, P=0.001 |
| SUVmean in liver | 10.4±2.1 | 10.1±2.4 | t=0.588, P=0.559 |
| SUVR of the tumor | 2.3±1.7 | 0.5±0.4 | Z=−4.894, P=0.001 |
| KS (grade/number) | 0/0, 1/11, 2/4, 3/7, 4/16 | 0/10, 1/8, 2/3, 3/0, 4/0 | Z=−5.163, P=0.001 |
PPGLs, pheochromocytomas/paragangliomas; PCC, pheochromocytoma; PGL, paraganglioma; VHL, von Hippel-Lindau syndrome; PNST, peripheral nerve sheath tumor; AA, adrenocortical adenoma; GIST, gastrointestinal stroma tumor; RSF, retroperitoneal solitary fibroma; AC, adrenocortical carcinoma; RCC, renal cell carcinoma; SUVmax, maximal standardized uptake value; SUVmean, mean standardized uptake value; SUVR, ratio between the SUVmax of the lesion and the SUVmean of the liver; KS, Krenning score.